Trial Profile

A Safety and immunogenicity of IXCHIQ® in children aged 1-11 in a LMIC, potentially located in Asia

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VLA 1553 (Primary)
Indications Chikungunya virus infections
Focus Adverse reactions; Therapeutic Use

Most Recent Events

04 Aug 2024 New trial record
22 Jul 2024 According to a Valneva media release, this trial is Part-funded by CEPI and the EU's Horizon Europe program, Trial partners, including clinical research organisations and trial sponsors, are expected to be selected over the coming months. Trial expected to start in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com